

Author Relationships With Industry and Other Entities (Comprehensive)—The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30–Year Journey (April 2014)

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Jeffrey L. Anderson	Intermountain Heart Institute, Intermountain Healthcare—Associate Chief of Cardiology	<ul style="list-style-type: none"> • The Medicines Company • Sanofi-aventis 	None	None	<ul style="list-style-type: none"> • Academic Research Group (DSMB) • Harvard (DSMB) • ICON Clinical Research (DSMB) • NIH* 	<ul style="list-style-type: none"> • NIH* 	None
Jonathan L. Halperin	The Cardiovascular Institute, Mount Sinai Medical Center, Division of Cardiology—Professor of Medicine	<ul style="list-style-type: none"> • AstraZeneca • Bayer • Biotronik† • Boehringer Ingelheim† • Boston Scientific • Bristol-Myers Squibb • Daiichi-Sankyo • Janssen Pharmaceuticals • Johnson & Johnson • Medtronic • Pfizer • Sanofi-aventis 	None	None	None	None	None
Alice K. Jacobs	Boston University School of Medicine—Professor of Medicine; Boston Medical Center, Department of Medicine—Vice Chair for Clinical Affairs	None	None	<ul style="list-style-type: none"> • Acetylon† 	<ul style="list-style-type: none"> • Abbott Vascular† • Boston Scientific • Bristol-Myers Squibb • Cordis • Daiichi-Sankyo • Eli Lilly • Medtronic Vascular • Sanofi-aventis 	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$10,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please

refer to <http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*No Financial Benefit.

†Significant relationship.

ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and NIH, National Institutes of Health.